ClinicalTrials.gg
CompletedNCT00191191Updated Dec 9, 2009Results posted

To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Pemetrexed 500 mg/m2 and Pemetrexed 1000 mg/m2 in Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 16 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-12-09.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
46th of 224
226 · median 65
Started
2004
with 2 others
Phase 2
128 of 228
12 open now
Registered
13th of 228
by date
Lead sponsor
40 of 228
Eli Lilly and Company

Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 46th largest by enrollment of the 224 interventional ones that give a count, is one of 3 that started in 2004, is one of 128 in phase 2, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical stage III or IV
  • Previously treated with one or two chemotherapeutic regimens
  • Performance status: 0-2

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to take folic acid or vitamin B12 supplementation
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    Pemetrexed 500 mg/m2

    Pemetrexed 500 mg/m2

    Drug: Pemetrexed 500 mg/m2

  • Experimental
    Pemetrexed 1000 mg/m2

    Pemetrexed 1000 mg/m2

    Drug: Pemetrexed 1000 mg/m2

Interventions

  • DrugPemetrexed 500 mg/m2

    Drug page: PemetrexedStudies of PemetrexedPemetrexed pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    500 mg/m2, intravenous (IV), every 21 days, one year from registration date

    Also known as: Alimta, LY231514

  • DrugPemetrexed 1000 mg/m2

    Drug page: PemetrexedStudies of PemetrexedPemetrexed pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1000 mg/m2, intravenous (IV), every 21 days, one year from registration date

    Also known as: Alimta, LY231514

06

What researchers measure

Primary outcomes

  1. Best Overall Response

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria as determined by the Case Judgment Committee. Best overall response was defined as the most favorable overall response recorded for each patient during the observation period. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

    Time frame: baseline to measured progressive disease (up to 3.2 years)

Secondary outcomes

  1. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression.

    Time frame: time of response to progressive disease (up to 3.2 years)

  2. Progression-Free Survival (PFS)

    PFS was defined as time from the scheduled date of the first treatment cycle until the date of confirmation of progressive disease on the overall response rating. For patients who died before confirmation of progressive disease, the number of days until the date of death (from any cause) was handled as progression-free survival.

    Time frame: baseline to measured progressive disease (up to 3.2 years)

  3. Change From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD)

    20-items assessed quality of life in patients undergoing chemotherapy. Scores range from 1 (not at all/very poor) to 5 (very much/very well). Face scale scores (patient circles number of the face that best fits his/her feelings) range from 1 (sad face) to 5 (smiling face). Item scores were grouped according to Functional (daily activity: 5 items), Physical (5 items), Emotional (psychological condition: 4 items), Social Attitude (5 items), and Face Scale (1 item). Score of subscales were converted to scores with range from 0 to 100. Higher scores represent higher QOL.

    Time frame: Baseline (pre-dose), 3 Months after first dose of Cycle 1

  4. Change From Baseline to 3 Months in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Lung Cancer Subscale (LCS)

    FACT-L LCS measured health-related quality of life (HR-QL) related to additional concerns of lung cancer. Original LCS subscale scores range from 0 to 28, but the scores were converted to scores with a range of 0 to 100 in this study. Higher scores represent better HR-QL.

    Time frame: Baseline (pre-dose), 3 Months after first dose of Cycle 1

07

Results

Posted Nov 25, 2009

Participant flow

Participant flow — Overall Study
MilestonePemetrexed 500 mg/m2Pemetrexed 1000 mg/m2
Started114112
Safety analysis population114111
Full analysis set population108108
Completed00
Not completed114112
Withdrew: Entry criteria exclusion20
Withdrew: Treated with another systemic agent11
Withdrew: Adverse event1121
Withdrew: Progressive disease8472
Withdrew: Toxicity after dose reduction78
Withdrew: Family/caregiver decision57
Withdrew: Lost to follow-up10
Withdrew: Physician decision32
Withdrew: Good clinical practice violation01

Outcome measures

PrimaryBest Overall Response

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria as determined by the Case Judgment Committee. Best overall response was defined as the most favorable overall response recorded for each patient during the observation period. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

Time frame:
baseline to measured progressive disease (up to 3.2 years)
Reported as:
Number · participants
Best Overall Response
participantsPemetrexed 500 mg/m2Pemetrexed 1000 mg/m2
Complete Response (CR)00
Partial Response (PR)2016
Stable Disease (SD)4034
Progressive Disease (PD)4858
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression.

Time frame:
time of response to progressive disease (up to 3.2 years)
Reported as:
Median · months
Duration of Response
monthsPemetrexed 500 mg/m2Pemetrexed 1000 mg/m2
Duration of Response4.9 (3.8 to 8.7)3.0 (2.8 to 6.1)
SecondaryProgression-Free Survival (PFS)

PFS was defined as time from the scheduled date of the first treatment cycle until the date of confirmation of progressive disease on the overall response rating. For patients who died before confirmation of progressive disease, the number of days until the date of death (from any cause) was handled as progression-free survival.

Time frame:
baseline to measured progressive disease (up to 3.2 years)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsPemetrexed 500 mg/m2Pemetrexed 1000 mg/m2
Progression-Free Survival (PFS)3.0 (2.0 to 3.5)2.5 (1.8 to 3.2)
SecondaryChange From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD)

20-items assessed quality of life in patients undergoing chemotherapy. Scores range from 1 (not at all/very poor) to 5 (very much/very well). Face scale scores (patient circles number of the face that best fits his/her feelings) range from 1 (sad face) to 5 (smiling face). Item scores were grouped according to Functional (daily activity: 5 items), Physical (5 items), Emotional (psychological condition: 4 items), Social Attitude (5 items), and Face Scale (1 item). Score of subscales were converted to scores with range from 0 to 100. Higher scores represent higher QOL.

Time frame:
Baseline (pre-dose), 3 Months after first dose of Cycle 1
Reported as:
Mean · units on a scale
Change From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD)
units on a scalePemetrexed 500 mg/m2Pemetrexed 1000 mg/m2
Functional Baseline (n=107, n=107)77.0 ± 24.8175.0 ± 26.18
Functional Change from Baseline (n=58, n=60)-1.5 ± 23.66-3.7 ± 19.99
Physical Baseline (n=107, n=107)78.9 ± 18.0273.9 ± 21.06
Physical Change from Baseline (n=58, n=60)-1.6 ± 18.27-3.5 ± 17.21
Emotional Baseline (n=107, n=107)67.2 ± 20.2162.1 ± 23.29
Emotional Change from Baseline (n=58, n=60)-1.7 ± 17.360.3 ± 20.10
Sociality Baseline (n=107, n=107)45.9 ± 22.0946.1 ± 22.37
Sociality Change from Baseline (n=58, n=60)1.6 ± 12.261.6 ± 17.05
Face Scale Baseline (n=107, n=107)59.3 ± 20.7559.3 ± 25.12
Face Scale Change from Baseline (n=58, n=60)-1.3 ± 20.64-2.1 ± 21.73
SecondaryChange From Baseline to 3 Months in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Lung Cancer Subscale (LCS)

FACT-L LCS measured health-related quality of life (HR-QL) related to additional concerns of lung cancer. Original LCS subscale scores range from 0 to 28, but the scores were converted to scores with a range of 0 to 100 in this study. Higher scores represent better HR-QL.

Time frame:
Baseline (pre-dose), 3 Months after first dose of Cycle 1
Reported as:
Mean · units on a scale
Change From Baseline to 3 Months in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Lung Cancer Subscale (LCS)
units on a scalePemetrexed 500 mg/m2Pemetrexed 1000 mg/m2
Baseline (n=107, n=107)71.5 ± 18.8169.6 ± 18.52
Change from Baseline (n=58, n=60)3.0 ± 16.130.4 ± 18.63

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed 500 mg/m2—19/114 (16.7%)114/114 (100%)
Pemetrexed 1000 mg/m2—21/111 (18.9%)111/111 (100%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPemetrexed 500 mg/m2Pemetrexed 1000 mg/m2
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders6/1143/111
PyrexiaGeneral disorders0/1145/111
PneumoniaInfections and infestations1/1142/111
Haemoglobin decreasedInvestigations0/1142/111
AnorexiaMetabolism and nutrition disorders0/1142/111
RashSkin and subcutaneous tissue disorders0/1142/111
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1141/111
Vertigo positionalEar and labyrinth disorders1/1141/111
DiarrhoeaGastrointestinal disorders1/1141/111
Gastric ulcer haemorrhageGastrointestinal disorders0/1141/111
Most frequent other events
Showing 10 of 72
Most frequent other events
EventPemetrexed 500 mg/m2Pemetrexed 1000 mg/m2
Aspartate aminotransferase increasedInvestigations88/11488/111
RashSkin and subcutaneous tissue disorders79/11487/111
Alanine aminotransferase increasedInvestigations81/11482/111
White blood cell count decreasedInvestigations80/11481/111
AnorexiaMetabolism and nutrition disorders56/11476/111
Neutrophil count decreasedInvestigations73/11474/111
Blood lactate dehydrogenase increasedInvestigations71/11471/111
Haemoglobin decreasedInvestigations59/11468/111
NauseaGastrointestinal disorders64/11464/111
Lymphocyte count decreasedInvestigations56/11464/111

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed 500 mg/m2Pemetrexed 1000 mg/m2Total
Mean60.8 ± 8.761.3 ± 8.861.1 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed 500 mg/m2Pemetrexed 1000 mg/m2Total
Female403979
Male6869137
Region of Enrollment
Region of Enrollment(participants)Pemetrexed 500 mg/m2Pemetrexed 1000 mg/m2Total
Japan108108216
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Pemetrexed 500 mg/m2Pemetrexed 1000 mg/m2Total
0 - Fully Active433679
1 - Ambulatory, Restricted Strenuous Activity5966125
2 - Ambulatory, No Work Activities6612
Histological Types
Histological Types(participants)Pemetrexed 500 mg/m2Pemetrexed 1000 mg/m2Total
Adenocarcinoma7780157
Squamous Cell Carcinoma232548
Large Cell Carcinoma516
Adenosquamous Carcinoma101
Other224
Height
Height(centimeters (cm))Pemetrexed 500 mg/m2Pemetrexed 1000 mg/m2Total
Mean161.0 ± 7.9161.1 ± 8.7161.0 ± 8.3
Weight
Weight(kilograms)Pemetrexed 500 mg/m2Pemetrexed 1000 mg/m2Total
Mean59.8 ± 9.959.1 ± 11.959.5 ± 10.9
08

Study locations

16 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Chiba, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Ehime, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Fukuoka, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Gifu, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Gunma, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Hokkaido, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Hyogo, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Kanagawa, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Kumamoto, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Miyagi, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Niigata, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Okayama, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Osaka, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Saitama, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Shizuoka, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Tokyo, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Oct 2004
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Nov 25, 2009
Last update
Dec 9, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191191
First posted
Sep 19, 2005
Start date
Oct 2004
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Nov 25, 2009
Last update
Dec 9, 2009

Study contacts

Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time(UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion